Market News

Analysts See $0.69 EPS for Emergent BioSolutions Inc. (EBS); Dermira, Inc. (DERM) Had 8 Bullish Analysts

Analysts expect Emergent BioSolutions Inc. (NYSE:EBS) to report $0.69 EPS on February, 22 after the close.They anticipate $0.05 EPS change or 6.76% from last quarter’s $0.74 EPS. EBS’s profit would be $33.59M giving it 17.62 P/E if the $0.69 EPS is correct. After having $0.73 EPS previously, Emergent BioSolutions Inc.’s analysts see -5.48% EPS growth. The stock decreased 2.68% or $1.34 during the last trading session, reaching $48.62. About 227,145 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has declined 23.64% since February 21, 2017 and is downtrending. It has underperformed by 40.34% the S&P500.

Among 9 analysts covering Dermira Inc (NASDAQ:DERM), 8 have Buy rating, 1 Sell and 0 Hold. Therefore 89% are positive. Dermira Inc had 21 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by Citigroup on Friday, December 18. The firm has “Buy” rating given on Thursday, September 7 by Mizuho. The stock of Dermira, Inc. (NASDAQ:DERM) earned “Buy” rating by Needham on Friday, September 15. The stock has “Buy” rating by Leerink Swann on Tuesday, November 7. The firm has “Buy” rating given on Monday, November 6 by Cantor Fitzgerald. The rating was maintained by Needham with “Buy” on Wednesday, May 11. Cowen & Co initiated the stock with “Outperform” rating in Wednesday, August 19 report. On Tuesday, December 12 the stock rating was maintained by Mizuho with “Buy”. Cantor Fitzgerald maintained Dermira, Inc. (NASDAQ:DERM) rating on Tuesday, July 25. Cantor Fitzgerald has “Buy” rating and $4500 target. As per Wednesday, January 17, the company rating was maintained by Leerink Swann. See Dermira, Inc. (NASDAQ:DERM) latest ratings:

17/01/2018 Broker: Leerink Swann Rating: Buy New Target: $48.0 Maintain
12/12/2017 Broker: Mizuho Rating: Buy New Target: $39.0 Maintain
05/12/2017 Broker: Guggenheim Rating: Buy Initiate
07/11/2017 Broker: Leerink Swann Rating: Buy New Target: $41.0 Maintain
07/11/2017 Broker: Needham Rating: Buy New Target: $43.0 Maintain
06/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $45.0 Maintain
15/09/2017 Broker: Needham Rating: Buy New Target: $46.0 Maintain
07/09/2017 Broker: Mizuho Rating: Buy Maintain

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company has market cap of $1.12 billion. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It currently has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

Since August 28, 2017, it had 0 insider buys, and 13 selling transactions for $1.59 million activity. Shares for $16,818 were sold by Cohen David E on Tuesday, January 2. Griffith Christopher M. sold $499,354 worth of Dermira, Inc. (NASDAQ:DERM) on Tuesday, January 2. The insider BAUER EUGENE A sold 3,000 shares worth $82,011. WIGGANS THOMAS G also sold $137,606 worth of Dermira, Inc. (NASDAQ:DERM) shares.

Investors sentiment increased to 2.03 in 2017 Q3. Its up 0.64, from 1.39 in 2017Q2. It is positive, as 15 investors sold Dermira, Inc. shares while 21 reduced holdings. 22 funds opened positions while 51 raised stakes. 41.09 million shares or 3.89% more from 39.55 million shares in 2017Q2 were reported. Ameriprise invested in 99,627 shares or 0% of the stock. Gsa Cap Ptnrs Llp invested in 0.05% or 25,770 shares. Geode Mgmt Lc stated it has 311,060 shares or 0% of all its holdings. Wells Fargo Mn, a California-based fund reported 52,995 shares. United Automobile Association holds 0% in Dermira, Inc. (NASDAQ:DERM) or 21,245 shares. Abingworth Ltd Liability Partnership reported 70,000 shares stake. Awm Inv Comm Inc has 0.35% invested in Dermira, Inc. (NASDAQ:DERM) for 75,000 shares. First Personal Fincl Ser invested in 0% or 707 shares. Ameritas Invest Inc invested in 0% or 3,345 shares. Point72 Asset L P owns 712,904 shares. Rhenman & Prns Asset Mgmt Ab owns 100,000 shares for 0.34% of their portfolio. Swiss Bancorporation has invested 0% in Dermira, Inc. (NASDAQ:DERM). Barclays Plc has invested 0% in Dermira, Inc. (NASDAQ:DERM). 2,928 were reported by Great West Life Assurance Can. Parallax Volatility Advisers Limited Partnership owns 0% invested in Dermira, Inc. (NASDAQ:DERM) for 5,704 shares.

The stock decreased 2.36% or $0.65 during the last trading session, reaching $26.84. About 439,415 shares traded. Dermira, Inc. (NASDAQ:DERM) has declined 7.44% since February 21, 2017 and is downtrending. It has underperformed by 24.14% the S&P500.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.37 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 27.07 P/E ratio. The company's marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.12, from 1.57 in 2017Q2. It is positive, as 11 investors sold Emergent BioSolutions Inc. shares while 48 reduced holdings. 34 funds opened positions while 66 raised stakes. 33.90 million shares or 1.32% less from 34.36 million shares in 2017Q2 were reported. Systematic Management Lp invested in 0.03% or 41,545 shares. First Republic Investment Mngmt Incorporated has 8,863 shares. Schwab Charles Inv Mngmt stated it has 617,823 shares. Loomis Sayles Lp has invested 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Chicago Equity Prtnrs Llc accumulated 46,365 shares or 0.06% of the stock. Qs Investors Ltd Llc owns 109,992 shares for 0.04% of their portfolio. Clark Cap holds 0.08% or 55,142 shares in its portfolio. Pnc Finance Group reported 929 shares. 43,681 were reported by Credit Suisse Ag. Axa holds 0.02% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 117,100 shares. Putnam Lc has 0% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 41,607 shares. Aperio Group Inc Ltd Llc owns 12,843 shares. 16,977 were reported by Citadel Advsr Limited Liability Corp. Citigroup Incorporated holds 0% or 53,776 shares in its portfolio. 35,455 were reported by New York State Teachers Retirement System.

Leave a Reply

Your email address will not be published. Required fields are marked *